Projects per year
Fingerprint
Dive into the research topics where Emmanuel Petricoin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Developing an algorithm for Molecular Tailored Therapy
Brody, J. J., Petricoin, E., Albanese, C., Madhavan, S. & Pishvaian, M. M.
Pancreatic Cancer Action Network, American Association for Cancer Research
1/01/15 → …
Project: Research
-
Developing an algorithm for Molecular Tailored Therapy
Brody, J. J., Petricoin, E., Pishvaian, M. M., Albanese, C. & Madhavan, S.
Pancreatic Cancer Action Network, American Association for Cancer Research
1/07/15 → 30/06/18
Project: Research
-
CGE25-106: MHC II More Effectively Predicts Response to Pembrolizumab Than PD-L1 in HER2 Negative Patients
Fogarty, E., Corgiat, B., Sparks, K., Arnell, C., Petricoin, E., Davis, J. & Mueller, C., 28 Mar 2025, In: JNCCN Journal of the National Comprehensive Cancer Network. 23, 35Research output: Contribution to journal › Article › peer-review
-
Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database
Levi, A., Blais, E., Davelaar, J., Ebia, M. I., Minasyan, A., Nikravesh, N., Gresham, G., Zheng, L., Chuy, J. W., Shroff, R. T., Wadlow, R. C., DeArbeloa, P., Matrisian, L. M. C., Petricoin, E., Pishvaian, M. J., Gong, J., Hendifar, A. E. & Osipov, A., 1 Mar 2025, In: Oncologist. 30, 3, oyaf007.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
Drizyte-Miller, K., Engstrom, L. D., Klomp, J. A., Stalnecker, C. A., Stamey, A. G., Taylor, K. E., Roach, M. K., Robb, R., Waters, L. M., Calinisan, A., Degan, S., Chang, W. H., Helu, X. M., Nguyen, D., Baldelli, E., Pierobon, M., Petricoin, E. F., Briere, D. M., Hallin, J., Christensen, J. G., & 4 others, 15 Sep 2025, In: Cancer Research. 85, 18, p. 3540-3557 18 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
DeLiberty, J. M., Roach, M. K., Stalnecker, C. A., Robb, R., Schechter, E. G., Pieper, N. L., Taylor, K. E., Pita, L. M., Yang, R., Bang, S., Drizyte-Miller, K., Ackermann, S. E., Nicewarner Peña, S. R., Baldelli, E., Min, S. M., Drewry, D. H., Petricoin, E. F., Morris, J. P., Der, C. J., Cox, A. D., & 1 others, 15 Apr 2025, In: Cancer Research. 85, 8, p. 1479-1495 17 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Defining the MYC-regulated transcriptome and kinome that support KRAS-and ERK-dependent growth of pancreatic cancer
Hibshman, P. S., Stalnecker, C. A., Klomp, J. A., Drizyte-Miller, K., Klomp, J. E., Cole Edwards, A., Pita, L. M., Hodge, R. G., Nathaniel Diehl, J., Mouery, R. D., Mouery, B. L., Snare, K. R., Waters, A. M., Peng, S., Barker, N. K., Pierobon, M., Rashid, N. U., Tran, N. L., Herring, L. A., Graves, L. M., & 4 others, 30 Sep 2025, In: Science Signaling. 18, 906, eadu7145.Research output: Contribution to journal › Article › peer-review
Press/Media
-
Reports on Precision Oncology Findings from Inova Health System Provide New Insights (Real-time functional proteomics enhances therapeutic targeting in precision oncology molecular tumor boards)
Nicholas Bateman, Thomas Conrads, Larry Maxwell & Emmanuel Petricoin
2/05/25
1 item of Media coverage
Press/Media
-
Studies in the Area of Cancer Reported from Inova Schar Cancer Institute (Quantitative Proteomic Analysis of Her2 Protein Expression In Pdac Tumors)
Nicholas Bateman, Thomas Conrads & Emmanuel Petricoin
29/11/24
1 item of Media coverage
Press/Media
-
-
Study Results from Inova Schar Cancer Institute Provide New Insights into Breast Cancer (Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer)
Thomas Conrads & Emmanuel Petricoin
27/09/24
1 item of Media coverage
Press/Media